I'm Voting NoFinancials are really looking great. Growth and catalysts for TRX alone have a bright future. Since Harris and Co. can not go out and solicit another competing bid for TRX these financials will serve as an attractive advertisement for the larger fish to take notice. Like kuato I am hoping for GUD (or another hungry big fish swimming in cash) to outbid the POZN deal.
I like Adams as CEO, I like Deerfield and the cash warchest they bring, the one thing I'm not sold on (and taking the biggest rish for) is Yosprala. This drug is aspirin and omeprazole (a proton pump inhibitor) and the more I read about omeprazole and proton pump inhibitors the more reservations I have with this merger. Take a little time and due diligence to google omeprazole and proton pump inhibitors and read some of the side effects of this drug. If they are going to market Yosprala as an every day drug I can foresee a lot of obstacles like patient complications, lawsuits, doctors refusing to recommend the drug, sales being less than stellar and that's assuming it gets approved.
I'd much rather vote "NO", grow TRX for a year or two (if not sooner) and eventually have it taken out, hopefully at a lot higher price than we currently sit. If you want some skin in the game with Yosprala buy it after the TRX "NO" vote on the cheap as POZN will surely sell off (might actually make a great speculative buy) while TRX will likely pop on the news. Thoughts?